After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

OpenAI said Tuesday it has reorganized its ownership structure and converted its business into a public benefit corporation after two crucial regulators, the Delaware and California attorneys general, ...

[Stay on top of transportation news: Get TTNews in your inbox.] A summer-like start to autumn across the heartland means that crop fields are rapidly drying out, forcing farmers to gather crops before ...

U.S. Soldiers assigned to the 173rd Airborne Brigade practice with the M249 light machine gun before testing on the weapon lanes at Grafenwöhr Training Area, Grafenwöhr, Sept. 17, 2025. Weapon lanes ...

Confluent Inc. (NASDAQ:CFLT) is one of the best low-priced technology stocks to buy right now. Confluent Inc. (NASDAQ:CFLT) is reinforcing its leadership bench and strategic focus at a critical stage ...

The debate about AI’s impact on consulting tends to swing between two extremes: Some argue that AI will render consultants obsolete; others claim it will only make them more indispensable. Both views ...

As demand for data centers increases across the world, Newsweek has mapped out every center in the U.S. The increasing demand for this kind of infrastructure comes at a time of increasing energy bills ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

The MarketWatch News Department was not involved in the creation of this content. PLANO, Texas, July 09, 2025 (GLOBE NEWSWIRE) -- Three specialized technology firms have merged under a team of proven ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...